Bravo
If ARM was an arm, BRN would be its biceps💪!
Ummm... ChatGPT reckons that regulatory scrutiny would actually be higher if BrainChip redomiciled to the U.S.!
It states:
But hang on a minute—wasn’t one of the key justifications for redomiciling the need to escape the burdens of ASX disclosure rules?
Something doesn’t quite add up. Either the company wants less scrutiny or it’s walking straight into more of it...
Question : BrainChip is considering redomiciling to the US. The share price is currently 25 cents and there has been very little traction in relation to the signing of new licences and the emergence of any decent revenue. Is it likely that BrainChip would confront a similar fate to Blaize with their disappointing experience listing on the NASDAQ?
Chat GPT's Answer: Given BrainChip's current circumstances—a low share price (25 cents), minimal revenue traction, and few new license agreements—a redomicile to the U.S. could indeed expose it to risks similar to those faced by Blaize, which suffered a 75% share price drop within months of its NASDAQ debut via SPAC.
Here’s a breakdown of how the two situations compare and why BrainChip might risk a similar fate if it proceeds without first strengthening fundamentals:
Unless BrainChip significantly strengthens its commercial foundation—first—then redomiciling to the U.S. risks repeating Blaize’s trajectory: high expectations, low delivery, and a rapid erosion of shareholder value.
It states:
“Regulatory Scrutiny: SEC filings are stricter; BrainChip may be forced to disclose more detailed financials and pipeline info, which could backfire if weak.”
But hang on a minute—wasn’t one of the key justifications for redomiciling the need to escape the burdens of ASX disclosure rules?
Something doesn’t quite add up. Either the company wants less scrutiny or it’s walking straight into more of it...
Question : BrainChip is considering redomiciling to the US. The share price is currently 25 cents and there has been very little traction in relation to the signing of new licences and the emergence of any decent revenue. Is it likely that BrainChip would confront a similar fate to Blaize with their disappointing experience listing on the NASDAQ?
Chat GPT's Answer: Given BrainChip's current circumstances—a low share price (25 cents), minimal revenue traction, and few new license agreements—a redomicile to the U.S. could indeed expose it to risks similar to those faced by Blaize, which suffered a 75% share price drop within months of its NASDAQ debut via SPAC.
Here’s a breakdown of how the two situations compare and why BrainChip might risk a similar fate if it proceeds without first strengthening fundamentals:
BrainChip vs Blaize – Risk Comparison
Factor | BrainChip (Now) | Blaize (at NASDAQ Listing) |
---|---|---|
Share Price | $0.25 AUD (~$0.17 USD) | $10.00 USD at listing |
Revenue | Minimal, with no clear breakout revenue reported | ~$2M TTM, net loss >$70M |
Licensing Traction | Sparse updates on commercial deals | Entered market with limited commercial success |
Investor Confidence | Waning, due to lack of visibility and delivery | High at listing, quickly eroded |
Valuation Expectations | Unclear, likely difficult to justify high valuation in U.S. | Valued at $894M, now down sharply |
Market Conditions | Still cautious around deep tech unless backed by revenue | Similar post-SPAC fatigue and skepticism |
Key Risks of Redomiciling Now
- Dilution Risk: A U.S. listing could involve raising capital at low valuation, diluting existing shareholders.
- Visibility ≠ Value: Without revenue, a U.S. move would only shine a brighter light on BrainChip's lack of commercial traction.
- Regulatory Scrutiny: SEC filings are stricter; BrainChip may be forced to disclose more detailed financials and pipeline info, which could backfire if weak.
- Investor Sentiment: NASDAQ investors are unforgiving if results don’t materialize quickly. A poor debut could destroy confidence permanently.
When Redomiciling Could Make Sense
- Signing multiple commercial licenses with global players.
- Demonstrating repeatable revenue and clear growth trajectory.
- Securing a credible cornerstone U.S. investor (e.g., Arm, Qualcomm).
- Showing robust customer pipeline metrics and use-case adoption.
Conclusion
Unless BrainChip significantly strengthens its commercial foundation—first—then redomiciling to the U.S. risks repeating Blaize’s trajectory: high expectations, low delivery, and a rapid erosion of shareholder value.